Durect (DRRX) Upgraded to Strong Buy: Here's Why
- Durect (DRRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 01/16/2025
|
New Strong Buy Stocks for January 9th
- AFRM, ZNTL, IMTX, MRCY and DRRX have been added to the Zacks Rank #1 (Strong Buy) List on January 9, 2024.
- 01/09/2025
|
Durect (DRRX) Upgraded to Buy: Here's What You Should Know
- Durect (DRRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 12/11/2024
|
DURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 Million
- CUPERTINO, Calif. , Nov. 25, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announced the sale of its ALZET® line of osmotic pumps to Lafayette Instrument Co. (LIC), a portfolio company of Branford Castle Partners II, L.P.
- 11/25/2024
|
DURECT Corporation (DRRX) Q3 2024 Earnings Call Transcript
- DURECT Corporation (NASDAQ:DRRX ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Jim Brown - Co-Founder, Chief Executive Officer, President, Director Tim Papp - Chief Financial Officer WeiQi Lin - Executive Vice President of Research and Development, Principal Scientist Conference Call Participants Thomas Yip - H.C. Wainwright Karl Burns - Northland Capital Markets Operator Greetings!
- 11/13/2024
|
Durect (DRRX) Reports Q3 Loss, Misses Revenue Estimates
- Durect (DRRX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.40 per share a year ago.
- 11/13/2024
|
DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update
- - Seeking to initiate Phase 3 registrational trial for larsucosterol with topline results expected within two years of initiation - Webcast of Earnings Call Today, November 13 at 4:30 p.m. ET CUPERTINO, Calif.
- 11/13/2024
|
DURECT Corporation to Announce Third Quarter 2024 Financial Results and Provide a Business Update
- CUPERTINO, Calif. , Nov. 6, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its third quarter financial results on Wednesday, November 13, 2024.
- 11/06/2024
|
DURECT Corporation to Present Data on Larsucosterol at The Liver Meeting 2024
- CUPERTINO, Calif. , Oct. 17, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announce that it will deliver an oral and two poster presentations at The Liver Meeting 2024, organized by the American Association for the Study of Liver Diseases (AASLD), to be held November 15-19, 2024 in San Diego, California.
- 10/17/2024
|
DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis
- - Type B meeting with FDA held under Breakthrough Therapy designation resulted in agreement on key aspects of Phase 3 trial design - Single Phase 3 trial designed to enroll 200 U.S. patients with a 90-day survival primary endpoint; topline results expected within two years of trial initiation - Protocol for Phase 3 trial builds on data from the AHFIRM Phase 2b trial; 30 mg and 90 mg doses of larsucosterol reduced 90-day mortality in U.S. patients by 57% and 58%, respectively, compared with placebo CUPERTINO, Calif. , Sept. 25, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today provided details on the design of its upcoming registrational Phase 3 trial which will evaluate larsucosterol for the treatment of patients with severe alcohol-associated hepatitis (AH).
- 09/25/2024
|
DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference
- CUPERTINO, Calif. , Sept. 4, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury and cancer, today announced management's participation in the H.C.
- 09/04/2024
|
DURECT Corporation (DRRX) Q2 2024 Earnings Call Transcript
- DURECT Corporation (NASDAQ:DRRX ) Q2 2024 Results Conference Call August 13, 2024 4:30 PM ET Company Participants Tim Papp - CFO & Secretary Jim Brown - Co-Founder, CEO, President & Director WeiQi Lin - EVP, Research & Development and Principal Scientist Conference Call Participants François Brisebois - Oppenheimer Ed Arce - H.C. Wainwright Carl Byrnes - Northland Capital Markets Operator Ladies and gentlemen, welcome to the DURECT Corporation Second Quarter 2024 Earnings Conference Call.
- 08/13/2024
|
Durect (DRRX) Reports Q2 Loss, Lags Revenue Estimates
- Durect (DRRX) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.46 per share a year ago.
- 08/13/2024
|
DURECT Corporation Reports Second Quarter 2024 Financial Results and Business Update
- - FDA Granted Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis - Held Type B Meeting with FDA to Discuss Phase 3 Clinical Trial Design - Seeking to Initiate Phase 3 Trial in 2024 with Topline Results Expected in 2H 2026 - Webcast of Earnings Call Today, August 13th at 4:30 p.m. ET CUPERTINO, Calif.
- 08/13/2024
|
DURECT Corporation to Announce Second Quarter 2024 Financial Results and Provide a Business Update
- CUPERTINO, Calif. , Aug. 7, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its second quarter financial results on Tuesday, August 13, 2024.
- 08/07/2024
|
Are Medical Stocks Lagging DURECT (DRRX) This Year?
- Here is how Durect (DRRX) and Elevance Health (ELV) have performed compared to their sector so far this year.
- 06/19/2024
|
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis
- DURECT plans to confirm the efficacy and safety of larsucosterol in a registrational Phase 3 clinical trial CUPERTINO, Calif. , May 21, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) to larsucosterol for the treatment of patients with severe alcohol-associated hepatitis (AH).
- 05/21/2024
|
DURECT Corporation (DRRX) Q1 2024 Earnings Call Transcript
- DURECT Corporation (NASDAQ:DRRX ) Q1 2024 Earnings Conference Call May 13, 2024 4:30 PM ET Company Participants Timothy M. Papp - CFO James E.
- 05/13/2024
|
Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates
- Durect (DRRX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.52 per share a year ago.
- 05/13/2024
|
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update
- - FDA Feedback Supports Single Pivotal Trial for Approval of Larsucosterol in Alcohol-Associated Hepatitis - Webcast of Earnings Call Today, May 13th at 4:30 p.m. ET CUPERTINO, Calif.
- 05/13/2024
|
DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update
- CUPERTINO, Calif. , May 7, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its first quarter financial results on Monday, May 13, 2024.
- 05/07/2024
|
DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis
- CUPERTINO, Calif. , April 30, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury and cancer, today announced acceptance of a late-breaking oral presentation at the European Association for the Study of the Liver (EASL) Congress 2024 to take place June 5-8, 2024 in Milan, Italy.
- 04/30/2024
|
Durect (DRRX) Reports Q4 Loss, Misses Revenue Estimates
- Durect (DRRX) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.46 per share a year ago.
- 03/27/2024
|
DURECT Corporation (DRRX) Q4 2023 Earnings Call Transcript
- DURECT Corporation (DRRX) Q4 2023 Earnings Call Transcript
- 03/27/2024
|
DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- - Ongoing Communication with FDA to Align on Next Steps for Larsucosterol in Alcohol-Associated Hepatitis - Webcast of Earnings Call Today, March 27th at 4:30 p.m. ET CUPERTINO, Calif.
- 03/27/2024
|
DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update
- CUPERTINO, Calif. , March 20, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its fourth quarter and full year 2023 financial results on Wednesday, March 27, 2024.
- 03/20/2024
|
DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada
- Partnership agreement will be the first-ever co-marketing and sales collaboration for the ALZET Osmotic Pumps Portfolio and Associated Product Line in the U.S. and Canada Both companies will jointly market and commercialize the ALZET product line to customers over a multi-year period CUPERTINO, Calif. , March 4, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), today announced that it has entered into a co-marketing and collaboration agreement with Charles River Laboratories for the ALZET® Osmotic Pumps Portfolio and Associated Product Line in the U.S. and Canada.
- 03/04/2024
|
DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- CUPERTINO, Calif. , Feb. 7, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that James E.
- 02/07/2024
|
Top 3 Health Care Stocks That Are Preparing To Pump This Month - Durect (NASDAQ:DRRX), Aadi Bioscience (NASDAQ:AADI)
- The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
- 12/18/2023
|
DURECT Corporation (DRRX) Q3 2023 Earnings Call Transcript
- DURECT Corporation (NASDAQ:DRRX ) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Tim Papp - Chief Financial Officer Jim Brown - Chief Executive Officer Conference Call Participants François Brisebois - Oppenheimer Carl Byrnes - Northland Capital Markets Thomas Yip - H.C. Wainwright Operator Good afternoon, everyone, and welcome to the DURECT Corporation Third Quarter Earnings Conference Call.
- 11/13/2023
|
DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update
- - Webcast of Earnings Call Today, November 13th at 4:30 p.m. ET - Topline data from AHFIRM trial showed compelling efficacy signal in favor of larsucosterol in the key secondary endpoint of mortality at 90 days CUPERTINO, Calif.
- 11/13/2023
|
DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update
- CUPERTINO, Calif. , Nov. 9, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its financial results for the three months ended September 30, 2023 on Monday, November 13, 2023.
- 11/09/2023
|
Why Is Durect (DRRX) Stock Down 64% Today?
- Durect (NASDAQ: DRRX ) stock is falling hard on Wednesday after the late-stage biopharmaceutical company released results from a Phase 2b clinical trial. This clinical trial covered the efficiency of larsucosterol in treating patients with severe alcohol-associated hepatitis.
- 11/08/2023
|
3 Promising Biotech Stocks That Will Make Early Investors Rich
- For investment ideas that can potentially lead to life-changing gains, few sectors are as viable as biotech stocks to make you rich. Fundamentally, the biotechnology sector offers potential therapeutic innovations that could change paradigms for patient care.
- 10/02/2023
|
DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis
- Company on track to report topline data from AHFIRM in Q4 2023 CUPERTINO, Calif. , Sept. 7, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the last patient has completed the study protocol in the Company's AHFIRM trial.
- 09/07/2023
|
DURECT Corporation Announces Presentations in Upcoming Investor Conferences
- CUPERTINO, Calif. , Aug. 31, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program , will present in the following September 2023 conferences.
- 08/31/2023
|
DURECT Corporation (DRRX) Q2 2023 Earnings Call Transcript
- DURECT Corporation (NASDAQ:DRRX ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Timothy Papp - CFO & Secretary James Brown - Co-Founder, CEO, President & Director WeiQi Lin - EVP, Research & Development and Principal Scientist Keith Lui - SVP, Business Development, Commercial & Medical Affairs Conference Call Participants Richard Miller - Cantor Fitzgerald Francois Brisebois - Oppenheimer Antonio Arce - H.C. Wainwright & Co. Sean Kim - JonesTrading Operator Greetings, and welcome to the DURECT Corporation Second Quarter Earnings Call.
- 08/09/2023
|
DURECT Corporation (DRRX) Q1 2023 Earnings Call Transcript
- DURECT Corporation (NASDAQ:DRRX ) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Tim Papp - Chief Financial Officer Jim Brown - Chief Executive Officer Keith Lui - Senior Vice President, Business Development, Commercial, Medical Affairs WeiQi Lin - Executive Vice President, Research and Development, Principal Scientist Norman Sussman - Chief Medical Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Ed Arce - H.C. Wainwright Francois Brisebois - Oppenheimer Sean Kim - Jones Trading Operator Greetings and welcome to the DURECT Corporation First Quarter 2023 Earnings Call.
- 05/08/2023
|
Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates
- Durect (DRRX) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.50 per share a year ago.
- 05/08/2023
|
DURECT Corporation to Announce First Quarter 2023 Financial Results and Provide Business Update on May 8
- CUPERTINO, Calif. , May 1, 2023 /PRNewswire/ --- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its first quarter 2023 financial results and host a conference call after the market close on Monday, May 8, 2023.
- 05/01/2023
|
DURECT Corporation to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor Conference
- CUPERTINO, Calif. , April 25, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James Brown, President and CEO, will participate in a fireside chat hosted by Ed Arce, Managing Director, Senior Biotechnology Research Analyst, H.C Wainwright & Co., LLC at the H.C.
- 04/25/2023
|
Durect (DRRX) Reports Q4 Loss, Tops Revenue Estimates
- Durect (DRRX) delivered earnings and revenue surprises of 13.21% and 2.79%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 03/07/2023
|
DURECT Corporation to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 7
- CUPERTINO, Calif. , Feb. 28, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its fourth quarter and full year 2022 financial results and host a conference call after the market close on Tuesday, March 7, 2023.
- 02/28/2023
|
Durect (DRRX) Soars 11.8%: Is Further Upside Left in the Stock?
- Durect (DRRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 01/11/2023
|
DURECT Corporation (DRRX) Q3 2022 Earnings Call Transcript
- DURECT Corporation (NASDAQ:DRRX ) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Tim Papp - Chief Financial Officer Jim Brown - Chief Executive Officer Norman Sussman - Chief Medical Officer Keith Louie - Business Development and Commercialization Conference Call Participants Kristen Kluska - Cantor Fitzgerald Operator Greetings. And welcome to the DURECT Corporation Third Quarter 2022 Earnings Conference Call.
- 11/02/2022
|
DURECT Corporation to Announce Third Quarter 2022 Financial Results and Provide Business Update on November 2
- CUPERTINO, Calif. , Oct. 26, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its third quarter 2022 financial results and host a conference call after the market close on Wednesday, November 2, 2022.
- 10/26/2022
|
DURECT Corporation's (DRRX) CEO Jim Brown on Q2 2022 Results - Earnings Call Transcript
- DURECT Corporation (NASDAQ:DRRX ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Tim Papp - Chief Financial Officer Jim Brown - Chief Executive Officer Norman Sussman - Chief Medical Officer Conference Call Participants Rick Miller - Cantor Fitzgerald Thomas Yip - H.C. Wainwright Operator Greetings.
- 08/06/2022
|
Durect (DRRX) Reports Q2 Loss, Lags Revenue Estimates
- Durect (DRRX) delivered earnings and revenue surprises of -25% and 59.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/04/2022
|
DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference
- CUPERTINO, Calif. , May 18, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E.
- 05/18/2022
|
DURECT Corp (DRRX) CEO James Brown on Q1 2022 Results - Earnings Call Transcript
- DURECT Corp, Inc. (NASDAQ:DRRX ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Matthew Hogan - IR James Brown - Co-Founder, CEO, President & Director Norman Sussman - Chief Medical Officer Conference Call Participants François Brisebois - Oppenheimer Thomas Yip - HC Wainwright Geoffrey de Sibert - KB Advisors Matthew Hogan Good afternoon, and welcome to our First Quarter 2022 Earnings Conference Call. This is Matt Hogan, from DURECT Corporation.
- 05/04/2022
|
DURECT Corporation To Present at the 2022 Cantor Fitzgerald Virtual Rare Orphan Disease Summit
- CUPERTINO, Calif., March 23, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E.
- 03/23/2022
|
DURECT Corporation's (DRRX) CEO Jim Brown on Q4 2021 Results - Earnings Call Transcript
- DURECT Corporation's (DRRX) CEO Jim Brown on Q4 2021 Results - Earnings Call Transcript
- 03/07/2022
|
Durect (DRRX) Reports Q4 Loss, Tops Revenue Estimates
- Durect (DRRX) delivered earnings and revenue surprises of 40% and 204.04%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 03/07/2022
|
Here's Why Durect (DRRX) is Poised for a Turnaround After Losing 17.1% in 4 Weeks
- Durect (DRRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 01/13/2022
|
DURECT Corporation (DRRX) CEO Jim Brown on Q3 2021 Results - Earnings Call Transcript
- DURECT Corporation (DRRX) CEO Jim Brown on Q3 2021 Results - Earnings Call Transcript
- 11/03/2021
|
Durect (DRRX) Reports Q3 Loss, Misses Revenue Estimates
- Durect (DRRX) delivered earnings and revenue surprises of 0.00% and -0.46%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/02/2021
|
Will Durect (DRRX) Report Negative Q3 Earnings? What You Should Know
- Durect (DRRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 10/25/2021
|
DURECT Corporation (DRRX) CEO Jim Brown on Q2 2021 Results - Earnings Call Transcript
- DURECT Corporation (DRRX) CEO Jim Brown on Q2 2021 Results - Earnings Call Transcript
- 07/29/2021
|
Durect (DRRX) Reports Q2 Loss, Misses Revenue Estimates
- Durect (DRRX) delivered earnings and revenue surprises of 0.00% and -16.56%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 07/29/2021
|
DURECT Corporation to Announce Second Quarter 2021 Financial Results and Provide Business Update on July 29
- CUPERTINO, Calif., July 22, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its second quarter 2021 financial results and host a conference call after the market close on Thursday, July 29, 2021.
- 07/22/2021
|
DURECT Corporation to Present at the 2021 Epigenetic Therapeutic Targets Virtual Summit
- CUPERTINO, Calif., July 14, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it will present at the Epigenetic Therapeutic Targets Summit, being held virtually July 13-15, 2021.
- 07/14/2021
|
Best Penny Stocks To Buy Now? 7 To Watch This Week
- What are the best penny stocks to buy this week? The post Best Penny Stocks To Buy Now?
- 06/20/2021
|
DURECT Corporation to Present Additional Clinical Data from DUR-928 Studies in NASH (Phase 1b) and in Hepatic Impairment (Phase 1) at Upcoming International Liver Conference 2021 (EASL)
- CUPERTINO, Calif., June 9, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it will present two posters at the 2021 International Liver Conference (EASL) to be held virtually June 23-26, 2021.
- 06/09/2021
|
DURECT's (DRRX) CEO Jim Brown on Q1 2021 Results - Earnings Call Transcript
- DURECT's (DRRX) CEO Jim Brown on Q1 2021 Results - Earnings Call Transcript
- 05/04/2021
|
Durect (DRRX) Reports Q1 Loss, Lags Revenue Estimates
- Durect (DRRX) delivered earnings and revenue surprises of 0.00% and -15.99%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/04/2021
|
Durect: Q1 Earnings Insights
- Shares of Durect (NASDAQ:DRRX) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were unchanged 0.00% year over year to ($0.05), which missed the estimate of ($0.04).
- 05/04/2021
|
Best Penny Stocks To Buy In May 2021? Take A Look At These Right Now
- Reddit penny stocks to watch as May 2021 gets kicked off The post Best Penny Stocks To Buy In May 2021? Take A Look At These Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/02/2021
|
DURECT Corporation to Announce First Quarter 2021 Financial Results and Provide Business Update on May 4
- CUPERTINO, Calif., April 27, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its first quarter 2021 financial results and host a conference call after the market close on Tuesday, May 4, 2021.
- 04/27/2021
|
DURECT Corporation (DRRX) CEO Jim Brown on Q4 2020 Results - Earnings Call Transcript
- DURECT Corporation (DRRX) CEO Jim Brown on Q4 2020 Results - Earnings Call Transcript
- 03/04/2021
|
Durect (DRRX) Reports Q4 Loss, Misses Revenue Estimates
- Durect (DRRX) delivered earnings and revenue surprises of -33.33% and -66.91%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 03/04/2021
|
Durect: Q4 Earnings Insights
- Shares of Durect (NASDAQ:DRRX) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 100.00% year over year to ($0.04), which missed the estimate of ($0.03).
- 03/04/2021
|
DURECT Corporation to Participate in Three Investor Conferences in March 2021
- CUPERTINO, Calif., March 3, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will partipate in three upcoming investor conferences, taking place in March 2021. All conferences will take place virtually. Details are as follow: H.C. Wainwright Life Sciences...
- 03/03/2021
|
Durect: Positive Data In Alcoholic Hepatitis, But Catalysts Too Far Away
- Durect has been all over the place, but its AH indication is the one that looks like its best bet. Phase 2a data was very positive.
- 02/24/2021
|
DURECT Corporation Announces Pricing of $42.5 Million Public Offering of Common Stock
- CUPERTINO, Calif., Feb. 4, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) ("DURECT"), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its...
- 02/04/2021
|
Durect stock soars 34% after it gets FDA approval for surgical pain treatment
- Shares of Durect Corp. gained 34.3% in premarket trading on Tuesday after the company said its drug, Posimer, had been approved by the Food and Drug Administration as a treatment for pain after a certain type of shoulder surgery. The drug is not an opioid.
- 02/02/2021
|
DURECT Corporation Announces U.S. FDA Approval of POSIMIR® For Post-Surgical Pain Reduction for up to 72 Hours Following Arthroscopic Subacromial Decompression
- CUPERTINO, Calif., Feb. 2, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that the U.S. Food and Drug Administration (FDA) has approved POSIMIR® (bupivacaine solution) for infiltration use in adults for administration into the subacromial space under direct...
- 02/02/2021
|
3 Fast-Growing Small Caps to Consider
- Investors who target growth could be interested in the following small-cap stocks, as they represent companies whose trailing 12-month net earnings per share improved significantly on a year-over-year basis.
- 02/01/2021
|
DURECT Corporation Announces Closing of LACTEL® Absorbable Polymer Product Line Sale to Evonik and Receipt of $15 Million
- CUPERTINO, Calif., Jan. 4, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that the sale of the LACTEL product line to Evonik closed and the $15 million payment was received on December 31, 2020. About DURECT Corporation DURECT is a biopharmaceutical company...
- 01/04/2021
|
DURECT Corporation to Sell its LACTEL® Absorbable Polymer Product Line to Evonik for $15 Million
- CUPERTINO, Calif., Dec. 7, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it has signed an agreement to sell its LACTEL Absorbable Polymer (LACTEL) product line to Evonik, a global leader in specialty chemicals. Under the terms of the agreement, Evonik will...
- 12/07/2020
|
DURECT Corporation (DRRX) CEO Jim Brown on Q3 2020 Results - Earnings Call Transcript
- DURECT Corporation (DRRX) CEO Jim Brown on Q3 2020 Results - Earnings Call Transcript
- 11/02/2020
|
Durect (DRRX) Reports Q3 Loss, Lags Revenue Estimates
- Durect (DRRX) delivered earnings and revenue surprises of -25.00% and -23.52%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
- 11/02/2020
|
DURECT Co. (NASDAQ:DRRX) Expected to Post Quarterly Sales of $4.03 Million
- Brokerages expect DURECT Co. (NASDAQ:DRRX) to post $4.03 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for DURECT’s earnings, with the highest sales estimate coming in at $4.60 million and the lowest estimate coming in at $3.25 million. DURECT posted sales of $10.76 million during […]
- 09/25/2020
|
Durect (DRRX) Investor Presentation - Slideshow
- The following slide deck was published by DURECT Corporation in conjunction with this event.
- 08/28/2020
|
IPO Update: PainReform Readies U.S. IPO Plan (Pending:PRFX)
- PainReform has filed to raise $23 million in a U.S. IPO.
- 08/06/2020
|
Oppenheimer: These 3 “Strong Buy” Stocks Could Double, If Not More
- The “dog days” of summer are here, but it’s just as busy as ever on the Street. As earnings results continue to roll in, investors will be watching for any update on the next economic stimulus package along with the non-farm payroll report slated for release this Friday. Against this backdrop, plenty of questions remain, weighing on the minds of both institutional and private investors.In a recent note to clients, Oppenheimer’s Chief Investment Strategist John Stoltzfus addresses these concerns. When it comes to stocks’ disconnected state, he writes that the market tends to focus on the future, with it betting on a successful outcome based on the stimulus policy already put in place. But will this highly accommodative monetary policy eventually cause inflation?“We do not expect high levels of inflation to result from the extraordinary stimulus and monetary policy taken to deal with the Covid-19 pandemic. Federal Reserve vigilance against inflation (as well as vigilance by central banks around the world) is likely to be able to suitably address any flare up of inflation,” Stoltzfus commented.Bearing this in mind, we took a closer look at three stocks backed by the analysts at Oppenheimer, the third best-performing research firm, according to TipRanks. Running the tickers through TipRanks’ database, we learned Oppenheimer sees at least 120% upside potential in store for each, and all three have earned a “Strong Buy” consensus rating from the rest of the Street.Durect Corporation (DRRX)Developing innovative therapies based on its endogenous epigenetic regulator program, Durect believes it could potentially transform the treatment of acute organ injury and chronic liver diseases. As one of its candidates has delivered encouraging results, Oppenheimer sees an opportunity to get in on the action.Firm analyst Francois Brisebois recently told clients, “After several years of promising results, we believe DRRX's endogenous small molecule epigenetic regulator DUR-928 has finally found its home in the treatment of Alcoholic Hepatitis (AH). Given a high level of mortality (26% 1-month rate) and no viable treatment options, we believe DUR-928's fairly early robust Phase 2a efficacy and safety data could have it attacking this ~ $3 billion market opportunity with peak penetration as early as 2025.”Digging a bit deeper into this Phase 2a data, along with a robust safety profile, the trial showed that the therapy was able to rapidly reduce bilirubin, a marker of AH. In addition, there was a 100% response to treatment from the Lille score (mortality predictor tool) in 30mg and 90mg dosages and reduction in MELD (AH severity). Going forward, AH Phase 2b is set to begin in 2H20. “Given the potential to receive Breakthrough Therapy Designation (BTD) for treating a life-threatening condition with a substantial improvement over available therapies (mainly corticosteroids), launch could happen ahead of anticipation. Additionally, market exclusivity and pricing could be greater if Orphan Drug Designation (ODD) is awarded based on ~117,000 annual hospitalizations,” Brisebois added.Plenty of other catalysts are still ahead, in Brisebois’ opinion. DUR-928 is being evaluated in hospitalized COVID-19 patients with acute liver or kidney injury in a Phase 2 study and Phase 1b NASH data could be released during an upcoming conference. It should also be noted that it’s a “waiting game” for Posimir’s PDUFA, with the analyst considering “any related weakness as a buying opportunity.”All of the above makes Brisebois optimistic about DRRX’s long-term growth prospects. As a result, the analyst continues to assign an Outperform rating and $7 price target to the stock. Should his thesis play out, a potential twelve-month gain of 202% could be in the cards. (To watch Brisebois’ track record, click here) Brisebois’ colleagues are also pounding the table on DRRX. Only Buy ratings, 4, in fact, have been issued in the last three months, so the consensus rating is a Strong Buy. At $6, the average price target implies shares could climb 156% higher in the next year. (See DRRX stock analysis on TipRanks)Avadel Pharmaceuticals (AVDL)Hoping to address overlooked and unmet medical needs, Avadel Pharmaceuticals wants to provide solutions through its patient-focused and cutting-edge products. With Oppenheimer stating its asset has “disruptive potential in a proven blockbuster market,” the firm believes it might be time to snap up shares. According to analyst Francois Brisebois, who also covers DRRX, AVDL is primarily focused on FT218, a once-nightly sodium oxybate designed for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. He goes so far as to call the candidate the company’s “first, second and third priorities,” noting that it recently sold its Hospital Drug Portfolio “to avoid distractions.”Looking at the pivotal Phase 3 REST-ON top-line data, Brisebois believes it “speaks for itself.” At the 9g dose, FT218 was able to produce a change from baseline in Maintenance of Wakefulness (MWT) of 10.82 minutes vs. 4.469 in placebo, in Clinical Global Impression-Improvement (CGI-I) of 72% vs. 31.6% and in Mean Weekly Cataplexy Attacks of -11.51 vs. -4.86, all three of the co-primary endpoints. “We were particularly impressed that the 6g and 7.5g doses also showed p<0.001 across all co-primary endpoints,” the analyst added.The implication? “Following strong efficacy and safety data, we believe FT218 could significantly disrupt Jazz Pharmaceuticals' Xyrem (twice-nightly sodium oxybate), which reported FY19 sales of $1.6 billion,” Brisebois said.While some investors have expressed concern regarding the company’s freedom to operate, Brisebois isn’t too worried. “We are comfortable with AVDL's freedom to operate path forward as we don't believe it will infringe on Xyrem's IP (REMS or DDI). Although FT218 does use the same drug substance, it consists of a substantially different drug product. The label should add more clarity,” he explained.Additionally, management has made a significant effort to drive a turnaround. Brisebois points out that since CEO Greg Divis was appointed in June 2019, he has offered clear guidance on enrollment, which has led to huge gains in the share price. He also mentioned, “Dr. Jordan Dubow's appointment as CMO was key because of his important role in adjusting the original study design (data a year ahead of expectations). New CFO Thomas McHugh's commercial experience is crucial.”Given everything that AVDL has going for it, it’s clear why Brisebois joined the bulls. In addition to initiating coverage with an Outperform rating, the analyst put a $19 price target on the stock. What does this mean for investors? Upside potential of 134% is at play.Overall, the bulls take the lead on this one. Out of 5 total reviews published in the last three months, all 5 analysts rated the stock a Buy. Therefore, the message is clear: AVDL is a Strong Buy. The $18.40 average price target implies shares could skyrocket 126% in the next twelve months. (See Avadel stock analysis on TipRanks)CymaBay Therapeutics (CBAY)Last but not least we have CymaBay Therapeutics, which develops therapies designed to improve the lives of patients with liver and other chronic diseases. Given its impressive technology, Oppenheimer has high hopes.Covering the stock for the firm, analyst Jay Olson points out that its seladelpar asset produced strong results in the ENHANCE Phase 3 study in PBC. As it was terminated early and there were only a small number of patients that reached 12 months, the primary endpoint was changed to 3 months. The revised primary composite and key secondary ALP normalization endpoints were both statistically significant at 10mg. “We believe these impressive efficacy results could set a new paradigm for physicians and patients as they strive to achieve ALP normalization,” the analyst commented.Going into more detail, 30% of patients in the study had moderate-to-severe pruritus, and the pruritus levels were balanced and representative of high-risk PBC patients, in Olson’s opinion. Unlike Ocaliva, which has a warning for severe pruritus with management strategies that include temporary dosing interruption, seladelpar was able to generate a substantial improvement in pruritus.Based on this promising data, CBAY could kick off a Phase 3 PBC study. “We expect CBAY to initiate this simplified Phase 3 PBC trial in 1Q21 with 12-month primary endpoint for pivotal data in 2023. The safety profile of seladelpar is similar to placebo and compares favorably to Ocaliva's which has a boxed warning for dosing in certain patients,” Olson stated.When it comes to the NASH indication, Phase 2b 52-week biopsy data, which showed a solid reduction in fibrosis and NASH resolution, could support seladelpar’s progression to Phase 3. It should be noted that CBAY might seek a partner here.With the company boasting a path forward in 2L PBC that could establish seladelpar as the standard of care, the deal is sealed for Olson. To this end, the analyst rates CBAY an Outperform (i.e. Buy) along with a $12 price target. This figure suggests 127.5% upside potential from current levels. (To watch Olson’s track record, click here) Looking at the consensus breakdown, other analysts echo Olson’s sentiment. With 8 Buys compared to no Holds or Sells, the word on the Street is that CBAY is a Strong Buy. In addition, the $12 average price target is identical to the Oppenheimer analyst’s. (See CBAY stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
- 08/05/2020
|
DURECT to Present at the BTIG Biotechnology Conference 2020
- DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer and Dr. WeiQi Lin, Executive Vice President of R&D will be participating in a fireside chat at the BTIG Biotechnology Conference 2020, Monday, August 10, 2020 at 11:00 a.m. EDT / 8:00 a.m. PDT. Institutional investors that are participating in the conference may request a virtual one-on-one meeting through the conference coordinators.
- 08/05/2020
|
Durect Corp (DRRX) Q2 2020 Earnings Call Transcript
- DRRX earnings call for the period ending June 30, 2020.
- 08/04/2020
|
Durect (DRRX) Q2 Earnings and Revenues Beat Estimates
- Durect (DRRX) delivered earnings and revenue surprises of 75.00% and 30.79%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- 08/03/2020
|
DURECT Corporation Announces Second Quarter 2020 Financial Results and Update of Programs
- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2020 and provided a corporate update.
- 08/03/2020
|
DURECT Corporation to Announce Second Quarter 2020 Financial Results and Provide Business Update on August 03
- DURECT Corporation (Nasdaq: DRRX) today announced that it will report second quarter 2020 financial results and host a conference call after the market close on Monday, August 3, 2020.
- 07/28/2020
|
Is It Too Late to Buy These 3 Pharmaceutical Stocks?
- Relmada Therapeutics, Neoleukin Therapeutics, and Durect were among the fastest-rising pharmaceutical stocks over the past year.
- 07/07/2020
|
Jane Street Group LLC Invests $379,000 in DURECT Co. (NASDAQ:DRRX)
- Jane Street Group LLC purchased a new position in shares of DURECT Co. (NASDAQ:DRRX) in the 1st quarter, HoldingsChannel.com reports. The institutional investor purchased 244,867 shares of the specialty pharmaceutical company’s stock, valued at approximately $379,000. A number of other large investors have also made changes to their positions in the stock. BRYN MAWR TRUST […]
- 07/02/2020
|
DURECT Corporation Announces Initiation of Patient Recruitment in Phase 2 Safety and Efficacy Study of DUR-928 in COVID-19 Patients with Acute Liver or Kidney Injury
- DURECT Corporation (Nasdaq: DRRX) today announced it has initiated recruiting patients for its randomized, double-blind, placebo-controlled, multi-center Phase 2 study to evaluate the safety and efficacy of DUR-928 in hospitalized COVID-19 infected patients with acute liver or kidney injury. The primary efficacy endpoint is a composite of survival and being free of acute organ failure at Day 28. The trial will enroll approximately 80 patients.
- 07/01/2020
|
DURECT (NASDAQ:DRRX) Receives Buy Rating from B. Riley
- B. Riley restated their buy rating on shares of DURECT (NASDAQ:DRRX) in a research note issued to investors on Monday morning, TipRanks reports. B. Riley currently has a $5.00 price objective on the specialty pharmaceutical company’s stock. DRRX has been the subject of several other research reports. ValuEngine raised DURECT from a hold rating to […]
- 06/30/2020
|
U.S. FDA seeks more data on Heron Therapeutics' non-opioid painkiller
|
DURECT Corporation Joins the Russell 3000® Index
- DURECT Corporation (Nasdaq: DRRX) today announced that it is set to join the broad-market Russell 3000® Index as a result of the 2020 Russell indexes annual reconstitution, effective after the US stock market opens today, June 29, 2020.
- 06/29/2020
|
-$0.04 Earnings Per Share Expected for DURECT Co. (NASDAQ:DRRX) This Quarter
- Equities research analysts expect that DURECT Co. (NASDAQ:DRRX) will post earnings per share of ($0.04) for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for DURECT’s earnings, with the lowest EPS estimate coming in at ($0.05) and the highest estimate coming in at ($0.03). DURECT also reported earnings of ($0.04) per share […]
- 06/29/2020
|
Durect (DRRX) Gets a Buy Rating from H.C. Wainwright - Markets
- In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Durect (DRRX – Research Report),
- 06/29/2020
|
B.Riley FBR Reaffirms Their Buy Rating on Durect (DRRX) - Markets
- In a report released today, Mayank Mamtani from B.Riley FBR reiterated a Buy rating on Durect (DRRX – Research Report),
- 06/29/2020
|
DURECT CORP : Termination of a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K) | MarketScreener
|
Gilead Terminates License Agreement for Long-Acting Injectable HIV Investigational Product
- DURECT Corporation (Nasdaq: DRRX) today announced that Gilead Sciences, Inc., (Gilead) has provided notice that, effective as of December 22, 2020, it is terminating the License Agreement dated July 19, 2019 and a related R&D; agreement between Gilead and DURECT related to the development and commercialization of a long-acting injectable HIV investigational product utilizing DURECT's SABER® technology.
- 06/26/2020
|
DURECT Corporation (DRRX): Hedge Funds Are Nibbling
- In this article we will take a look at whether hedge funds think DURECT Corporation (NASDAQ:DRRX) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips from […]
- 06/26/2020
|
4 ways alcohol negatively impacts the quality of your sleep
|
Top Pharmaceutical Stocks for Q3 2020
- These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q3 2020.
- 06/11/2020
|
DURECT to Present at the Jefferies 2020 Virtual Health Care Conference
- DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and CEO, will be presenting at the Jefferies 2020 Virtual Health Care Conference, Wednesday, June 3, 2020 at 10:00 a.m. EDT / 7:00 a.m. PDT. Institutional investors and analysts that are participating in the conference may request a virtual one-on-one meeting through the conference coordinators.
- 05/28/2020
|
HC Wainwright & Co. Maintains Buy on Durect, Raises Price Target to $6
|
DURECT Corporation Announces Positive Topline Data from Phase 1b Study of DUR-928 in NASH
- DURECT Corporation (Nasdaq: DRRX) today announced positive topline results from its Phase 1b clinical study of orally administered DUR-928 in nonalcoholic steatohepatitis (NASH) patients.
- 05/26/2020
|
Billionaire Jim Simons Pulls the Trigger on These 3 Healthcare Stocks
- Despite COVID-19's devastating impact, one legendary stock picker might have just cracked the market code. While the broader market tumbled, investing firm Renaissance Technologies and its founder Jim Simons could mark 2020 as a year of record-smashing growth. Since the start of this year through April 14, the firm’s core Medalian hedge fund notched a 24% gain.So, how has Simons managed to do it? When the professor and mathematician left the world of academia and launched Renaissance in 1982, he fundamentally changed the investing process, pioneering a new quantitative approach that relies on algorithms to uncover patterns in the market. Using this strategy, the firm has become one of the best-performing quant shops on the Street.Traditional methods like relying on intuition, speaking with companies and analyzing balance sheets didn’t stand a chance against Simons and his computer models. Medallion has returned 66% per year, or 39% after fees, since 1998, leaving other gurus like Warren Buffet and Ray Dalio in the dust. While Simons, who is now worth an estimated $23 billion, remains active at the firm but doesn’t directly oversee the fund anymore, he is in a league of his own, and is considered one of the all-time investing greats.Looking at Renaissance’s recent activity as a starting point, we poured through its latest 13F filing in an attempt to find compelling opportunities among its purchases. Narrowing in on three healthcare stocks, TipRanks’ database revealed that each is also admired by the analyst community, enough so to earn a “Strong Buy” consensus rating. It doesn’t hurt that all three sport some serious upside potential as well. Durect Corporation (DRRX)Using its endogenous epigenetic regulator program, Durect develops innovative treatments for acute organ injuries and chronic liver diseases. While it has experienced a pullback recently, some believe the weakness presents a buying opportunity. Among the bulls is Simons’ firm. In the last quarter, Renaissance gave its DRRX holding a boost when it added 989,000 shares. Its new position, which now lands at 5,208,212 shares, is valued at $8,073,000.Turning now to the Wall Street analysts, several take an optimistic approach when it comes to DRRX, including B.Riley FBR’s Mayank Mamtani. To back up his bullish thesis, the five-star analyst cites management’s update on the progress of lead development candidate, DUR-928, an epigenetic modulator. According to the company’s announcement, it’s collaborating with the FDA to study DUR-928 in a Phase 2 clinical trial involving COVID-19 patients in the hospital with acute organ injury.In preclinical studies, DUR-928 has already been able to stabilize mitochondria, modulate inflammatory responses and promote cell survival and tissue regeneration. Additionally, Mamtani points out that the candidate “may play an important role for up to half of hospitalized patients with COVID-19 reported to have had elevated liver enzyme levels, indicative of liver injury and more than a third of hospitalized patients reported to have kidney damage.” He added, “We are encouraged by DRRX's commitment to leverage DUR-928's unique mechanism to help combat the public health crisis, with an incremental cost of ~$3 million that has relatively limited impact on cash runway.” That being said, DUR-928's potential extends beyond COVID-19. Enrollment for the Phase 1b open label NASH program has been completed, with top-line data slated for release in Q2. The company has also been ramping up preparations to initiate a Phase 2b program for IV-administered DUR-928 in severe alcoholic hepatitis (AH) patients. These preparations include reaching an agreement on trial design and key study endpoints with the FDA. It should be noted that enrollment is now expected to begin in the second half of 2020 thanks to COVID-19-related impacts.As for its other candidate, POSIMIR, the company is currently managing information requests (IRs) regarding the NDA review. Mamtani thinks this “suggests an active engagement of agency in the review process.”Taking into account everything DRRX has to offer, Mamtani stated, “Given the recent pullback, we find both an undervalued AH opportunity and NT catalysts in top-line Phase 1b NASH results and the POSIMIR decision to offer an additional attractive entry point for DRRX shares.”To this end, Mamtani left a Buy rating and $5 price target on the stock. Should this target be met, a twelve-month gain of 100% could be in store. (To watch Mamtani’s track record, click here)Do other analysts agree with Mamtani? It turns out that they do. With 100% Street support, or 3 Buy ratings to be exact, the message is clear: DRRX is a Strong Buy. At $5.25, the average price target implies 110% upside potential. (See Durect stock analysis on TipRanks)Heron Therapeutics (HRTX)By applying innovative science and technologies with well-known pharmacology, Heron hopes to develop patient-focused solutions that address unmet medical needs. While HRTX did receive a CRL regarding its HTX-011 product, some believe it has the potential to be a best-in-class drug for post-operative pain.One of its fans is Renaissance. The billionaire’s fund snapped up 870,892 shares, increasing its HRTX holding by a whopping 482%. As for the new value of Renaissance’s position, it comes in at over $12.3 million.Wall Street analysts also have good things to say about HRTX. Representing Leerink, analyst Ami Fadia notes that HTX-011 review is on track for the June 26 PDUFA date, based on HRTX’s recent conversation with the FDA. Management also stated that the FDA communications suggest things are progressing well, with label discussions not expected to kick off before early June. With respect to HTX-011's CE marking in the EU, there will be a delay as a result of COVID-19, but management thinks the decision could come in the second half of 2020 and that the device shouldn’t encounter any review issues.Calling the HTX-011 growth opportunity underappreciated, Fadia argues “HTX-011's potential is supported by the strong pain reduction, safety, and opioid-sparing data from the Phase 3, and the total knee arthroplasty (TKA) and breast augmentation nerve block Phase 2b data.” She added, “We believe management has taken the appropriate steps to resolve the issues in the CRL, the additional three-month delay is not reflective of additional issues specific to HTX-011, and management can get approval by the June 26, 2020, PDUFA date.”On top of this, COVID-19 has had a relatively limited impact on Cinvanti sales, and the asset has held up well as arbitrage progresses. “Management remains confident in growth back in the franchise starting 2021, recapturing not only the clinic share lost during the arbitrage period but also continuing to gain share among those clinics that have been waiting until post arbitrage before adopting Cinvanti,” Fadia said.Bearing this in mind, Fadia stayed with the bulls. Along with an Outperform call, she reiterated the $26 price target. This target conveys her confidence in HRTX’s ability to climb 64% higher in the next year. (To watch Fadia’s track record, click here)With only Buy ratings assigned in the last three months, 6 to be exact, the consensus is unanimous: HRTX is a Strong Buy. In addition, the $38 average price target is more aggressive than Fadia’s and implies 136% upside potential. (See Heron stock analysis on TipRanks)Aurinia Pharmaceuticals (AUPH)Last up to bat, we have Aurinia, which wants to transform the way autoimmune diseases are treated. As its Voclosporin therapy represents a huge opportunity, Wall Street is getting behind this healthcare company.Simons’ firm didn’t miss out on an opportunity to tack on more shares to its AUPH holding. Renaissance bought up 860,266 shares, bringing its total stake in the company to 1,438,800 shares. After the position was bumped up by 149%, the new value is $20.9 million.Meanwhile, Cowen analyst Ken Cacciatore also likes what he’s seeing. He points out that the rolling NDA submission for Voclosporin, a next-generation calcineurin inhibitor that blocks IL-2 expression and T-cell mediated immune responses, in lupus nephritis (LN) is moving right on track, and should be completed by the end of Q2. This means that an approval could potentially come in the first half of 2021. “Our conviction in this management team and opportunity remains unchanged. This asset is still materially discounted at this valuation level, in our view,” he commented.According to Cacciatore, the robust results from the Phase 3 AURORA study “confirmed Voclosporin’s safety profile, clarifying the prior imbalance in deaths from the low-dose Voclosporin arm in Phase 2.” The analyst added, “Based on these results, and given the unmet need and significant market opportunity in LN, we believe Voclosporin could easily reach $1 billion-plus in this indication alone.”When it comes to AUPH’s intellectual property, Cacciatore thinks it is strong enough to enable more durability than others might expect. Expounding on this, he said, “Specifically, our legal consultants believe the patent claim of dose adjustments based on eGFR – and the unexpected findings of potentially improved efficacy at those lowered optimized doses – appears solid and defendable (after a full review of the prosecution history). And we believe the Voclosporin label will include language describing these findings/instructions, meaning generics would infringe.”Based on the clear pathway to approval for Voclosporin, most likely via a priority review, and the strength of its intellectual property, the deal is sealed for Cacciatore. As a result, he maintained an Outperform rating and $30 price target. Given this target, shares could rise 77% in the next twelve months.
- 05/20/2020
|
DURECT Corporation: DUR-928 May Benefit COVID-19 Patients With Acute Organ Injury
- I have previously recommended DURECT Corporation for its drug, DUR-928, which is being studied in NASH and alcoholic hepatitis, and soon, in COVID-19 patients w
- 05/13/2020
|
84 Biggest Movers From Yesterday
|
Durect Corp (DRRX) Q1 2020 Earnings Call Transcript
- Image source: The Motley Fool. Durect Corp (NASDAQ: DRRX)Q1 2020 Earnings CallMay 11, 2020, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGreetings, and welcome to the Durect Corporation First Quarter 2020 Results Conference Call.
- 05/12/2020
|
Here's Why Shares of Durect Jumped Higher Today
- Shares of Durect (NASDAQ: DRRX) were up 23% at 1:53 p.m. EDT on Tuesday. The gains followed the release of first-quarter results after the closing bell Monday and disappointing trial results for Genfit (NASDAQ: GNFT), a fellow biotech developing a potential competitor to Durect's nonalcoholic steatohepatitis (NASH) drug. It certainly wasn't Durect's financial report from the first quarter that has investors excited.
- 05/12/2020
|
60 Stocks Moving In Tuesday's Mid-Day Session
|
Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates
- Durect (DRRX) delivered earnings and revenue surprises of -25.00% and -41.41%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- 05/11/2020
|
Durect Q1 EPS $(0.050) Misses $(0.040) Estimate, Sales $2.800M May Not Compare To $7.190M Estimate
|
DURECT Corporation Announces First Quarter 2020 Financial Results and Update of Programs
- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2020 and provided a corporate update.
- 05/11/2020
|
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
- The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...
- 05/10/2020
|
DURECT Corporation to Announce First Quarter 2020 Financial Results and Provide Business Update on May 11
- CUPERTINO, Calif., May 4, 2020 DURECT Corporation (Nasdaq: DRRX) today announced that it will report first quarter 2020 financial results and host a conference call after the market close on Monday, May 11, 2020.
- 05/04/2020
|
Durect (DRRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
- Durect (DRRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/28/2020
|
Durect (DRRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
|
Durect Is A Biotech To Watch With Key Catalysts In 2020
- DURECT expects an FDA decision for its postoperative pain drug POSIMIR in the coming months, FDA approval will allow biotech to search for commercial partner. A
- 04/09/2020
|
DURECT Co. (NASDAQ:DRRX) Given Consensus Rating of "Buy" by Analysts
- Shares of DURECT Co. (NASDAQ:DRRX) have been assigned an average recommendation of “Buy” from the seven ratings firms that are presently covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have […]
- 04/06/2020
|
Edited Transcript of DRRX earnings conference call or presentation 3-Mar-20 9:30pm GMT
- Q4 2019 DURECT Corp Earnings Call
- 03/24/2020
|
B.Riley FBR Remains a Buy on Durect (DRRX)
- In a report issued on March 13, Mayank Mamtani from B.Riley FBR maintained a Buy rating on Durect (DRRX), with a price target of $5.00. The company's
- 03/16/2020
|
B.Riley FBR Remains a Buy on Durect (DRRX)
- In a report issued on March 13,
Mayank Mamtani
from B.Riley FBR maintained a
Buy
rating on Durect (
DRRX
–
Research Report
), with a price target of
$5.00
. The company’s shares closed last Monday at $1.50.
According to
TipRanks.com
, Mamtani has 0 s
- 03/16/2020
|
Shares of several companies in the healthcare space are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.
|
92 Biggest Movers From Yesterday
- Gainers
Cellect Biotechnology Ltd. (NASDAQ: APOP) shares jumped 45% to close at $3.03 on Wednesday. Cellect Biotechnology and Canndoc Ltd. agreed to enter into strategic pharma...
- 03/05/2020
|
DURECT shares are trading higher after the company reported better-than-expected Q4 sales results.
|
The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 3) * Acceleron Pharma Inc (NASDAQ: XLRN) * BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) * Fate Therapeutics Inc (NASDAQ: FATE) (reacted to its fourth-quarter
- 03/04/2020
|
Analysts Are Bullish on These Healthcare Stocks: Antares Pharma (ATRS), Durect (DRRX)
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Antares Pharma (ATRS) and Durect (DRRX) with bullish
- 03/04/2020
|
Analysts Are Bullish on These Healthcare Stocks: Antares Pharma (ATRS), Durect (DRRX)
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Antares Pharma (
ATRS
–
Research Report
) and Durect (
DRRX
–
Research Report
) with bullish sentiments.
Antares Pharma (ATRS)
In a report released today,
- 03/04/2020
|
38 Stocks Moving in Wednesday's Pre-Market Session
|
10 Stocks Moving In Tuesday's After-Hours Session
- Gainers
Ambarella (NASDAQ: AMBA) shares are trading higher after the company reported better-than-expected Q4 EPS and sales results. The company also issued Q1 sales...
- 03/03/2020
|
DURECT Corporation Announces Fourth Quarter and Full Year 2019 Financial Results and Update of Programs
- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months and year ended December 31, 2019 and provided a corporate update.
- 03/03/2020
|
The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 2) Forty Seven Inc (NASDAQ: FTSV )( announced a deal to be bought by Gilead Sciences, Inc. (NASDAQ: GILD )) IGM Biosciences Inc (NASDAQ: IGMS ) Iovance Biotherapeutics Inc (NASDAQ: IOVA ) Karyopharm Therapeutics Inc (NASDAQ: KPTI )(announced positive late-stage results for selinexor) Passage Bio Inc (NASDAQ: PASG )(IPOed Friday) Syneos Health Inc (NASDAQ: SYNH ) Trillium Therapeutics Inc (NASDAQ: TRIL )(moved in sympathy with Forty Seven, as it has a similar drug in the pipeline for solid tumor) Zynex Inc. (NASDAQ: ZYXI ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 2) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Akorn, Inc. (NASDAQ: AKRX ) ANI Pharmaceuticals Inc (NASDAQ: ANIP )(moved lower despite FDA nod for a generic version of Teva Pharmaceutical Industries Ltd's (NYSE: TEVA ) Alzheimer's related dementia drug) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Eagle Pharmaceuticals Inc (NASDAQ: EGRX ) (reacted to its fourth-quarter results) Evolus Inc (NASDAQ: EOLS ) EXACT Sciences Corporation (NASDAQ: EXAS ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) Imv Inc (NASDAQ: IMV ) Neurometrix Inc (NASDAQ: NURO ) Portola Pharmaceuticals Inc (NASDAQ: PTLA ) Precigen Inc (NASDAQ: PGEN ) Taro Pharmaceutical Industries Ltd. (NYSE: TARO ) Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) TherapeuticsMD Inc (NASDAQ: TXMD ) Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) Viking Therapeutics Inc (NASDAQ: VKTX ) Related Link: How The COVID-19 Outbreak Is Benefiting Biotech Investors Stocks In Focus GenMark Starts Shipping COVID-19 Test Kits GenMark said it has begun shipping ePlex Research Use Only, or RUO, test kits to detect COVID-19 virus.
- 03/03/2020
|
DURECT shares are trading higher after the company reported better-than-expected Q4 sales results.
|
The Week Ahead In Biotech: COVID-19 Stocks In The Spotlight, Earnings Taper Off
- Biotech stocks came under significant weakness along with the broader market in the week ended Feb. 28. Despite fears the COVID-19 epidemic will likely drag global growth, the viral outbreak proved advantageous for some biotechs that disclosed plans to work on therapies or vaccines for countering the viral attack. The FDA approved Esperion Therapeutics Inc's (NASDAQ: ESPR ) LDL-cholesterol lowering combo therapy and Biohaven Pharmaceutical Holding Co Ltd's (NYSE: BHVN ) migraine drug . The following are key catalysts that could move biotech stocks in the unfolding week. Conferences Cowen 40th Annual Healthcare Conference: March 2-4 in Boston, Massachusetts Related Link: Regeneron Snags Upgrade On Reduced Prospects For Rival Eye Disorder Drug Earnings Monday Albireo Pharma Inc (NASDAQ: ALBO ) (before the market open) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) (before the market open) Intra-Cellular Therapies Inc (NASDAQ: ITCI ) (before the market open) Seres Therapeutics Inc (NASDAQ: MCRB ) (before the market open) Urogen Pharma Ltd (NASDAQ: URGN ) …
- 02/29/2020
|
DURECT Corporation to Announce 2019 Financial Results on March 3
- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its fourth quarter and year ended December 31, 2019 financial results and host a conference call after the market close on Tuesday, March 3, 2020.
- 02/26/2020
|
Durect shares are trading higher. Not seeing any news to justify the price action.
|
These are the most popular sustainability stocks from the US | Finder
- With climate change becoming a major focus in Australia and around the world, leaders in the sustainability arena could become the big market winners.
- 02/12/2020
|
Durect shares are trading higher. Not seeing any company-specific news to justify the price action.
|
3 “Strong Buy” Healthcare Stocks With Triple-Digit Upside
- To buy or not to buy, that’s the question. For even the most seasoned Wall Street observers, determining the ideal time to pull the trigger on a particular stock can be a challenge. These decisions involve considering what type of gains are expected, more consistent growth achieved over the long haul or rapid upward climbs.More risk-tolerant investors are often drawn to the latter, enticed by the possibly of sky-high returns delivered at the drop of a hat. So, where can these stocks with huge upside potential be found? The healthcare sector. Its nature positions many companies to see their share prices multiply as a single update can either send shares through the roof or down the drain.With this in mind, we set out on our own search to find compelling plays in this volatile industry. Given the sheer size of the market, we used TipRanks’ Stock Screener tool to uncover 3 healthcare stocks that the analysts believe can double in the next year. In fact, each has attracted enough support from Wall Street to earn a “Strong Buy” consensus rating.Rockwell Medical (RMTI)Focusing on end-stage renal disease (ESRD) and chronic kidney disease (CKD), Rockwell Medical develops innovative therapies to help improve the lives of patients. Even with its leading iron maintenance therapy, Triferic, already receiving FDA approval for use in dialysis patients, analysts believe that its growth story is just getting started.The company announced on January 14 that it had finalized a license and supply agreement with Sun Pharma, a subsidiary of Sun Pharmaceutical Industries Ltd., for the rights to commercialize Triferic. Based on the terms of the agreement, RMTI will receive an undisclosed upfront sum to provide the therapy to Sun Pharma, who will be its exclusive development and commercialization partner in India. The company is also entitled to royalties on net sales and milestone payments.As Sun Pharma is the largest pharmaceutical company in India, boasting over $4 billion in annual sales, and there are about 120,000 patients receiving hemodialysis in the country, it’s no wonder the Street is excited. Citing Sun Pharma’s standing in the Indian pharmaceutical market, H.C. Wainwright analyst Raghuram Selvaraju sees the agreement as boding well for the company. “We note Sun Pharma's acquisitive business strategy and believe that Sun may eventually have interest in acquiring the Triferic franchise if it demonstrates rapid growth,” he explained.Furthermore, the company's IV Triferic is approaching its March PDUFA date, and Selvaraju points out that the drug is capable of reaching peak sales.As a result, the five-star analyst left his Buy rating and $11 price target unchanged. Should the target be met, a 402% twelve-month gain could be in the cards. (To watch Selvaraju’s track record, click here)Brandon Folkes of Cantor Fitzgerald added, "Beyond the India opportunity, we expect meaningful news flow from RMTI this year. A U.S. approval of IV Triferic is expected in 2020, as well as a submission of the IV formulation in Canada, potential approval of Triferic in Chile, and updates on the China and EU opportunities. All of which have the potential to drive positive inflections for the stock this year [...] We believe Triferic is an innovative product that will drive significant value for RMTI shareholders. We expect product approvals and upward earnings revisions in our DCF model to drive RMTI's stock higher."Bearing this in mind, he stayed with the bulls, reiterating his Overweight call. At $11, his price target matches Selvaraju’s. (To watch Folkes’ track record, click here)With 100% Street support, the message is clear: Rockwell Medical is a Strong Buy. Adding to the good news, the average price target of $9.33 puts the upside potential at 326%. (See Rockwell Medical price targets and analyst ratings on TipRanks)Durect Corporation (DRRX)Biopharma company Durect has definitely had a rough going recently. Following an AdCom’s split vote after reviewing its Posimir treatment for post-surgical pain, shares dipped 12% premarket. That being said, two members of the Street just told investors that they are still optimistic enough to get on board.One of the analysts singing DRRX’s praises is B.Riley FBR’s Mayank Mamtani, highlighting its “first and only-of-its kind treatment, DUR-928, for multiple liver diseases, notably alcoholic hepatitis (AH).” He noted, “We believe that the strong efficacy and excellent safety observed with DUR-928 therapy in the Phase 2a trial has paved the path for late-stage development and primarily contributed to the 600%-plus stock move in 2019. We also believe that DUR-928 has the potential to become a part of combination treatment regimens for nonalcoholic steatohepatitis (NASH).”Additionally, Mamtani points to its transition away from legacy operations associated with drug delivery platforms and its potential to be a partner for a larger biopharma name as making it a standout. In line with his bullish take, the five-star analyst started coverage with a Buy rating and $5 price target. (To watch Mamtani’s track record, click here)Like Mamtani, Craig-Hallum’s Francois Brisebois sees huge potential based on DUR-928. “We believe shares are undervalued today given the opportunity for DUR-928 in AH alone, to which we have ascribed the vast majority of our valuation,” he commented. The analyst adds, “It’s hard to overstate DUR-928’s market potential in AH. We derive a TAM of $3 billion based upon the 117,000 annual hospitalizations and what we see as a fairly conservative $25,000 one-time cost of therapy given that hospitalizations cost are over $50,000 per patient in the first year.”It comes as no surprise, then, that Brisebois initiated coverage by publishing a bullish call. At the $6 price target, shares could soar 277% over the next twelve months. (To watch Brisebois’ track record, click here)In general, the rest of the Street is on the same page. 4 Buys and 1 Hold assigned in the last three months coalesce into a Strong Buy analyst consensus. Not to mention the $4.72 average price target implies 197% upside potential. (See Durect stock analysis on TipRanks)Zynerba Pharmaceuticals (ZYNE)Specializing in transdermal cannabinoid therapies, Zynerba wants to help patients suffering from Fragile X syndrome (FXS), a condition that can cause anxiety, social withdrawal and violent outbursts. On the heels of its announcement that it successfully achieved its patient screening target in its pivotal CONNECT-FX trial, which is evaluating its topical cannabinoid Zygel in children and adolescents with FXS, some believe that huge gains are in store.With pivotal results expected in June, Ladenburg Thalmann & Co. analyst Michael Higgins thinks the development team’s experience, Phase 2 results, CBD’s anxiolytic activity and the recruitment make a strong data readout very likely. On top of this, he believes management’s strategy of enrolling patients with more severe FXS will pay off. “We agree with management that along with the increased dosing the enrollment criteria should ensure Zygel’s efficacy in treating problematic FXS behaviors will be most appropriately demonstrated,” he explained.Even though Zynerba is a single-product company, Higgins points out that it has at least three events coming up in its second quarter and other regulatory, clinical and marketing-based events in 2020 that could prove to be major catalysts. These include Phase 3 CONNECT-FX data, which if positive could result in Fast Track designation, as well as data from the Phase 2 BRIGHT, Phase 2 INSPIRE and from Phase 2 DEE trials. In addition, Zygel could meet the needs of patients with autism spectrum disorder, 22q11.2 deletion syndrome and rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies, three other large market indications.To this end, Higgins kept his Buy rating and $26 price target as is. This conveys his confidence in ZYNE’s ability to skyrocket 417% in the next twelve months. (To watch Higgins’ track record, click here)Looking at the consensus breakdown, it has been relatively quiet when it comes to analyst activity as only two other reviews have been issued recently. However, both were bullish, making the consensus rating a Strong Buy. It also doesn’t hurt that the $18.67 average price target brings the potential twelve-month gain to 271%. (See Zynerba stock analysis on TipRanks)
- 02/10/2020
|
Daily Insider Ratings Round Up 2/6/20
- Tables of the top insider purchases and sales filed with the SEC on 2/6/20, based on dollar value. Dollar values often do not equate with significance when it c
- 02/08/2020
|
5 Stocks Under $5 With Colossal Growth Prospects
- While some argue you get what you pay for, others say that stocks to buy trading at low levels can represent compelling opportunities.
- 01/31/2020
|
Baird downgrades Amgen on soft guidance in premarket analyst action
- AdaptHealth (NASDAQ:AHCO) initiated with Buy rating and $17 (31% upside) price target at Stifel.DURECT (NASDAQ:DRRX) initiated with Buy rating and $5 (158% upside) price target at B. Riley FBR. Shares
- 01/31/2020
|
B. Riley Initiates Coverage On Durect with Buy Rating, Announces $5 Price Target
|
4 Specialty & Generic Drug Manufacturer Stocks Moving In Monday's After-Market Session
- Gainers
• China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) shares moved upwards by 9.9% to $1.22 during Monday's after-market session.
• Akorn, Inc. (NASDAQ:AKRX)...
- 01/28/2020
|
20 Specialty & Generic Drug Manufacturer Stocks Moving In Monday's Session
|
HEXO, NIO among premarket gainers
- One Stop Systems (NASDAQ:OSS) +56% reports prelim results.Genprex (NASDAQ:GNPX) +52%.Akcea Therapeutics (NASDAQ:AKCA) +14% as antisense candidate successful in mid-stage hypertriglyceridemia study.Tri
- 01/22/2020
|
5 Drug Manufacturers—Specialty & Generic Stocks Moving In Tuesday's After-Market Session
- Gainers
• Assertio Therapeutics, Inc. (NASDAQ:ASRT) stock moved upwards by 3.1% to $1.34 during Tuesday's after-market session.
Losers
• Durect, Inc. (NASDAQ:...
- 01/22/2020
|
82 Biggest Movers From Yesterday
|
Durect shares are trading lower in sympathy with the broader market as anxiety around the coronavirus outbreak in China spreads to global markets. NOTE: An FDA AdCom panel voted to discuss an NDA for POSIMIR, 6 voted for, and 6 voted against
|
The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares
- The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 16.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Arvinas Inc (NASDAQ: ARVN ) AtriCure Inc. (NASDAQ: ATRC ) AVITA MED LTD/S ADR (NASDAQ: RCEL ) ChemoCentryx Inc (NASDAQ: CCXI ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) DENTSPLY SIRONA Inc (NASDAQ: XRAY ) Eli Lilly And Co (NYSE: LLY ) Epizyme Inc (NASDAQ: EPZM ) Fate Therapeutics Inc (NASDAQ: FATE ) Foamix Pharmaceuticals Ltd (NASDAQ: FOMX ) Fortress Biotech (NASDAQ: FBIO ) (announced award of pediatric disease designation for its partner company Cyprium's CUTX-101, which is being evaluated for Menkes disease) Frequency Therapeutics Inc (NASDAQ: FREQ ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Hologic, Inc. (NASDAQ: HOLX ) HEALTH SCIENCES/SH (NASDAQ: IMVT ) Inspire Medical Systems Inc (NYSE: INSP ) Insulet Corporation (NASDAQ: PODD ) Johnson & Johnson (NYSE: JNJ Medtronic PLC (NYSE: MDT ) Masimo Corporation (NASDAQ: MASI ) Medpace Holdings Inc (NASDAQ: MEDP ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Mesoblast limited (NASDAQ: MESO ) Minerva Neurosciences Inc (NASDAQ: NERV ) Nantkwest Inc (NASDAQ: NK ) …
- 01/17/2020
|
DURECT Corporation Announces Outcome of FDA Advisory Committee Meeting for POSIMIR®
- DURECT Corporation (Nasdaq: DRRX) today announced that the U.S. Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) met yesterday to discuss the Class 2 New Drug Application (NDA) resubmission for POSIMIR® (bupivacaine extended-release solution). In a split vote on the key question, six advisory committee members voted to recommend that the efficacy, safety, and overall risk-benefit profile of POSIMIR support approval, while six did not support approval based on the information presented.
- 01/17/2020
|
38 Stocks Moving In Friday's Mid-Day Session
|
U.S. FDA panel split over approval of Durect's non-opioid painkiller
|
The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on Jan. 15)
10X Genomics Inc (NASDAQ...
- 01/16/2020
|
DURECT Corporation Trading Halted Today; FDA Advisory Committee to Discuss POSIMIR® (bupivacaine extended-release solution) for Post-Surgical Analgesia
- DURECT Corporation (Nasdaq: DRRX) today announced that NASDAQ has halted trading of the Company's common stock today.
- 01/16/2020
|
DURECT Issues Press Release Highlighting Halt In Stock Ahead Of FDA AdCom Panel To Discuss POSIMIR For Post-Surgical Analgesia
|
Durect shares are trading higher. The stock moved higher following unusual interest in next month's $2.5 call contract.
|
The Week Ahead In Biotech: JPMorgan Healthcare Conference, FDA Panel Reviews Opioid Pain Drugs, I-Mab's IPO
- Activity in the biotech space is likely to pick up this week. Events are likely to be headlined by the annual JPMorgan Healthcare Conference. Biotech stocks closed 2019 with gains, although they underperformed relative to the broader market. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) closed up 25.2% in 2019 compared to the S&P 500's 29% jump. The new year is likely to bring several challenges for biotech stocks, the chief among them being a hard political stance on drug pricing ahead of the year's elections. The following are key catalysts that could take the spotlight this week. Conferences 38th Annual JPMorgan Healthcare Conference: Jan. 13-16 in San Francisco, California. Adcom Meetings A joint Tuesday meeting of the FDA's Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee will discuss Nektar Therapeutics' (NASDAQ: NKTR ) NDA for oxycodegol , a NME … Full story available on Benzinga.com
- 01/12/2020
|
Durect shares are trading lower. Not seeing any company-specific news to justify the price action.
|
53 Biggest Movers From Friday
|
30 Stocks Moving In Friday's Mid-Day Session
|
Drug developer dips on failed psoriasis trial
- Shares of drug developer Durect Corp. shed nearly a third of their value Thursday after the Cupertino company said its headline drug failed a mid-stage clinical trial aimed at people with itchy, scaly psoriasis. Durect's drug, called DUR-928, has been closely watched not only because of of the psoriasis study but because it also is being tested as a treatment for alcoholic hepatitis and nonalcoholic steatohepatitis, or NASH — a fatty liver disease that is one of the hottest potential commercial opportunities for drug developers. Then Durect disclosed the topline data from the psoriasis trial, and the stock opened at $2.50 and sunk as low as $2.05.
- 01/02/2020
|
DURECT Corporation Announces Top-Line Results from Phase 2a Clinical Trial in Patients with Psoriasis
- DURECT Corporation (Nasdaq: DRRX) today announced the results from its Phase 2a clinical trial of DUR-928 in patients with mild to moderate plaque psoriasis. Twenty-two patients completed the study, applying DUR-928 topically to the plaque on one arm and the vehicle (placebo) to a similar plaque on the other arm daily for 28 days.
- 01/02/2020
|
Mid-Afternoon Market Update: Signet Jewelers Falls Following Wells Fargo Downgrade; Trillium Therapeutics Shares Surge
|
Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates
- In a final push before the closing of the year, the FDA deemed it fit to clear even long pending ones, including Flexion Therapeutics Inc's (NASDAQ: FLXN ) sNDA for the updation of the label for its osteoarthritis drug Zilretaa. About seven new molecular entities, or NMEs, were approved in the month, including Allergan plc's (NYSE: AGN ) migraine treatment Ubrelvy and Sarepta Therapeutics Inc's (NASDAQ: SRPT ) Duchenne muscular dystrophy drug Vyondys 53 . A NME is a drug that contains an active ingredient, which hasn't been approved by the FDA previously, either as a single ingredient drug or as part of a combination product. The number of NME approvals is considered a measure of innovation among biotechs. NME approvals for the year totaled 48, a sizable number, although paling in significance before 2018's 59. There was rejection too, with the FDA turning down Correvio Pharma Corp's (NASDAQ: CORV ) atrial fibrillation drug Brinavess. Related Link: 10 Biotech M&A Targets Under The Scanner For 2020 PDUFA dates are deadlines for the FDA to review new drugs.
- 01/01/2020
|
38 Stocks Moving In Tuesday's Mid-Day Session
|
3 Healthcare Stocks With Huge FDA Decisions in January
- In the stock market, sometimes all it takes is a single catalyst to propel shares to sky-high levels. This is especially common with healthcare stocks. While they carry significant risk, these names rely on only a few key milestones such as favorable trial data or attaining FDA approval, so a single dose of good news can have a big impact on share prices.The latter is particularly important as drug or medical device approval from the regulatory agency can lead to sustainable revenues for a company. No wonder, then, that investor focus locks in on healthcare companies ahead of decisions from the FDA.Bearing this in mind, we took a closer look at 3 healthcare stocks awaiting huge decisions from the FDA in January. TipRanks, a company that measures and tracks the performance of analysts, revealed that Wall Street sees each of these names as solid Buys. Here’s what we uncovered.Durect Corporation (DRRX) Recognized for its expertise in both formulation and drug delivery, Durect focuses on developing novel treatments for chronic kidney disease as well as acute organ injury. Its lead candidate, DUR-928, is an orally bioavailable small molecule that’s part of the company’s Epigenetic Regulator program. Representing a new class of therapeutics, it could play a key role in cellular functions like lipid homeostasis, inflammation and cell survival.That being said, the attention directed at DRRX is related to its POSIMIR candidate, designed to provide non-opioid pain relief after surgery. While still commonly used, opioids often have undesirable side effects and can be highly addictive. With 72 million surgical procedures performed each year in the U.S., there is a large unmet need for alternative forms of pain management.On January 16, an AdCom meeting will take place to determine if the FDA will recommend POSIMIR approval for the post-surgical analgesia indication.H.C. Wainwright analyst Ed Arce notes that his bullish thesis remains very much intact. He argues that the company’s submission of new data and re-analysis of the integrated summary of safety bode well for FDA approval.“PERSIST was designed based on extensive consultation and feedback from the FDA, and DURECT has successfully compiled a safety database with over 260 patients in the study to sufficiently address the issues raised in the CRL…We believe POSIMIR's data portfolio that was built upon efficacy data from two completed trials and safety data of all 16 completed trials, assembled under Dr. Simon's guidance, is sufficient to support POSIMIR's approval,” the analyst explained.Based on this conclusion, the five-star analyst told investors that he is staying with the bulls, reiterating the Buy rating. At his $4 price target, shares could surge 23% in the coming twelve months. (To watch Arce’s track record, click here)Cantor's Eliana Merle set a more aggressive price target along with her Buy rating based on not only POSIMIR but also DUR-928’s potential as a treatment for Alcoholic hepatitis (AH), for which there is a huge opportunity. Should the $5 target be met, investors could see 53% upside. (To watch Merle’s track record, click here)Judging from the consensus breakdown, it has been relatively quiet when it comes to other analyst activity. Over the last three months, only 2 analysts have reviewed the biopharma. Both of which, however, were bullish, making the consensus a Moderate Buy. On top of this, the $4.50 average price target puts the upside potential at 38%. (See Durect stock analysis on TipRanks)Aimmune Therapeutics (AIMT)Switching gears now, Aimmune takes aim at food allergies. The biopharma develops new treatments for people with potentially life-threatening food allergies. While shares are up 37% in 2019, investors want to know if AIMT has more fuel in the tank as it approaches the FDA decision for its lead candidate.PALFORZIA (AR101), its oral immunotherapy (OIT) treatment of peanut allergy, could see an approval decision come in late January 2020 for its use in the U.S., with the EU approval outcome expected in the second half of the year. Back in September, the company got a piece of good news as the FDA’s Allergenic Products Advisory Committee (APAC) voted in favor of approval for the therapy’s use in pediatric patients with peanut allergies.In addition to the vote of confidence from the panel, Wedbush’s Liana Moussatos sees a clear path to approval based on “robust efficacy and safety data to date.” Despite different regions of study, entry criteria, dosing periods and primary endpoints, both of the Phase 3 studies indicated consistent results. If that wasn’t promising enough, the analyst forecasts more than $1.5 billion in annual sales worldwide starting in 2023 if PALFORZIA is in fact approved. To this end, Moussatos left the Outperform rating and $79 price target unchanged. This conveys her confidence in AIMT’s ability to skyrocket 142% in the year ahead. (To watch Moussatos’ track record, click here)Meanwhile, Christopher Raymond of Piper Jaffray cites a recent meeting with management as reason for his bullish approach. He came away with a much more optimistic take on PALFORZIA’s launch. “We are much more confident that Palforzia’s launch can meaningfully outperform expectations, both near- and long-term. Coupling this with the stock’s 30% short interest, we like the opportunity for meaningful upside into this drug’s late January expected approval and launch,” the five-star analyst noted. As a result, Raymond maintained both the bullish call and $60 price target. (To watch Raymond’s track record, click here)Is the rest of the Street in agreement? As it turns out, the analyst consensus is more of a mixed bag. Split almost right down in the middle, 3 Buy ratings and 4 Holds were assigned in the last three months, giving AIMT Moderate Buy status. With a $44.14 average price target, the potential twelve-month gain comes in at 35%. (See Aimmune stock analysis on TipRanks)Epizyme (EPZM) Through the use of targeted epigenetic medicines, Epizyme is developing treatments for cancer and other serious diseases. Ahead of the January 23 PDUFA date for its primary product candidate, tazemetostat, all eyes are on the company.Looking at the results of the AdCom that took place earlier this month, it’s clear why investors have been getting excited. The panel voted unanimously to support the approval of tazemetostat for use in epithelioid sarcoma. Even though there was some concern about an open-label single-arm study, the panelists were impressed by the duration of response for a small indication with high unmet need, its safety and tolerability profile, its efficacy in a second-line (2L) setting and the limited amount of available treatment options.While the outcome doesn’t mean that final FDA approval is a sure thing, the Street is certainly buzzing. Since the AdCom vote, shares have climbed 24% higher, pushing EPZM’s 2019 rise to a whopping 267%.Jeffries analyst Michael Yee believes the AdCom should ease concerns about a possible FDA rejection. “Bottom line: we think the outcome today partially de-risks EPZM's follicular lymphoma program (NDA filing by YE:19) and should enable the company to transition to a commercial stage company by 2020,” he commented. With this in mind, Yee left the Buy rating and $21 price target as is. (To watch Yee’s track record, click here)Like Yee, Morgan Stanley’s David Lebovitz has high hopes for EPZM, pointing out that the FDA usually adheres to the recommendations of its AdCom panels. This prompted the analyst to keep the Overweight rating and $24 price target, suggesting 11% upside potential. (To watch Lebovitz’s track record, click here)Turning now to the rest of the Street, other analysts are on the same page. Based on the 6 Buy ratings vs no Holds or Sells, the Strong Buy consensus comes in just like the AdCom vote, unanimously. Given the recent uptick to the share price, the $20.33 average price target implies 10% downside. (See Epizyme stock analysis on TipRanks)
- 12/30/2019
|
38 Healthcare Stocks Moving In Monday's Pre-Market Session
|
Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus
- Biotech stocks advanced in the penultimate week of the year, and the iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) is on track to end the year with gains in excess of 25%. The previous week saw FDA announcements on verdicts for several therapeutic options. Notable among the therapeutic options that crossed the FDA hurdle were Allergan plc (NYSE: AGN )'s migraine drug; Flexion Therapeutics Inc (NASDAQ: FLXN )'s Zilretta, which was given a label expansion; Intra-Cellular Therapies Inc (NASDAQ: ITCI )'s schizophrenia drug; and two generics for Eliquis, a blood thinner marketed by Bristol-Myers Squibb Co (NYSE: BMY ) and Pfizer Inc. (NYSE: PFE ). However, Correvio Pharma Corp (NASDAQ: CORV )'s Brinavess, a drug to treat atrial fibrillation, stumbled at the FDA altar. A big gene therapy collaboration agreement between Roche Holdings AG Basel ADR (OTC: RHHBY ) and Sarepta Therapeutics Inc (NASDAQ: SRPT ) was announced. The following are key biotech catalysts for the unfolding week: PDUFA Dates The FDA is scheduled to rule on the pancreatic cancer drug candidate lynparza, which is being co-developed by AstraZeneca plc (NYSE: AZN ) and Merck & Co., Inc. (NYSE: MRK ).
- 12/29/2019
|
Durect Option Alert: Jul 17 $5 Puts Sweep (9) near the Bid: 500 @ $2.5 vs 0 OI; Ref=$3.109
|
The Daily Biotech Pulse: Qiagen Opts To Stay Solo Following Strategic Review, Spectrum Slumps On Negative Data, Microbot Medical To Offer Shares
- The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 24.) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Applied Genetic Technologies Corp (NASDAQ: AGTC ) Cassava Sciences Inc (NASDAQ: SAVA ) ChemoCentryx Inc (NASDAQ: CCXI ) Clearside Biomedical Inc (NASDAQ: CLSD ) DURECT Corporation (NASDAQ: DRRX ) Eiger Biopharmaceuticals Inc (NASDAQ: EIGR ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Exagen Inc (NASDAQ: XGN ) Forty Seven Inc (NASDAQ: FTSV ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Harpoon Therapeutics Inc (NASDAQ: HARP ) Horizon Therapeutics PLC (NASDAQ: HZNP ) HEALTH SCIENCES/SH (NASDAQ: IMVT ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Kodiak Sciences Inc (NASDAQ: KOD ) (JPMorgan initiated coverage with an Outperform rating) Microbot Medical Inc (NASDAQ: MBOT ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc.
- 12/26/2019
|
The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict
|
Stocks That Hit 52-Week Highs On Monday
|
DURECT (DRRX) Investor Presentation - Slideshow
|
Cantor Fitzgerald Assumes Durect at Overweight, Announces $5 Price Target
|
Durect Corporation Announces Results From Phase 2A Clinical Trial Of DUR-928 In Alcoholic Hepatitis Patients In A Late-breaking Presentation At The Liver Meeting; All Patients Treated With DUR-928 In Trial Survived 28-Day Follow-Up Period
|
The Week Ahead In Biotech: Adcom Test For Amarin's Fish Oil Pill, Agile Awaits FDA Verdict
|
Beirne Wealth Consulting Services, LLC Buys ARK Innovation ETF, iShares Core U.S. ...
|
Durect Q3 EPS $(0.01) Misses $0.02 Estimate, Sales $10.8M Miss $15.7M Estimate
|
DURECT Corporation: DUR-928 Data In Severe Alcoholic Hepatitis To Be Showcased At Upcoming AASLD Meeting
|
Durect (DRRX) Investor Presentation - Slideshow
|
DURECT Reports DUR-928 Phase 2a Study Results Selected For Late-Breaking Oral Presentation At 2019 The Liver Meeting
|
Durect shares are trading higher on seemingly no company-specific news.
|
DURECT Announces Completion of Enrollment in its Phase 2a Clinical Trial of DUR-928 in Psoriasis and 50% Enrollment in its Phase 1b DUR-928 Clinical Trial in NASH
|
Durect shares are trading higher after the company announced the FDA Advisory Committee plans to meet to review POSIMIR for the treatment of post-surgical pain.
|
Durect Corp shares are trading lower likely on profit taking after the stock has seen continuous upward momentum over the last 30 days. Not seeing any news to justify the price action.
|
Shares of small-cap drugmaker Durect are trading lower. Shares have rallied this month and are potentially selling off.
|
Durect shares are trading higher despite no company-specific news. The stock has rallied approximately 45% in the past month.
|
The Daily Biotech Pulse: Sandoz Recalls Ulcer Drug, Anchiano Strikes Agreement With ADT Pharma, Proteon Announces Reverse Merger
- The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 23.) Applied Therapeutics Inc (NASDAQ: APLT ) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) ( announced a communication from the FDA allowing it to proceed with a reduced sample size in a Phase 3 study of its drug to treat excessive daytime sleepiness) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Celgene Corporation (NASDAQ: CELG ) Cesca Therapeutics Inc (NASDAQ: KOOL ) DURECT Corporation (NASDAQ: DRRX ) Enlivex Therapeutics Ltd (NASDAQ: ENLV ) Sanofi SA (NASDAQ: SNY ) SpringWorks Therapeutics Inc (NASDAQ: SWTX ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Down In The Dumps (Biotech stocks that hit 52-week lows Sept. 23) Aduro BioTech Inc (NASDAQ: ADRO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Akcea Therapeutics Inc (NASDAQ: AKCA ) (announced departures of CEO, president and COO, and the appointment of board member Damien McDevitt as interim CEO) BioNano Genomics Inc (NASDAQ: BNGO ) Catalyst Biosciences Inc (NASDAQ: CBIO ) Cellectis SA (NASDAQ: CLLS ) Clovis Oncology Inc (NASDAQ: CLVS ) (announced acquisition of rights to FAP-targeted radiopharmaceuticals from 3B Pharmaceuticals for $12 million) Erytech Pharma SA (NASDAQ: ERYP ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) Kalvista Pharmaceuticals Inc (NASDAQ: KALV ) KITOV PHARMA LT/S ADR (NASDAQ: KTOV ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Neon …
- 09/24/2019
|
Stocks That Hit 52-Week Highs On Monday
|
34 Stocks Moving In Monday's Mid-Day Session
|
Durect shares are trading higher. Not seeing any news to justify the price action. The stock has seen continued upward momentum over the past 3 months.
|
Durect shares are trading higher. Not seeing any news to justify the price action.
|
Stifel Nicolaus Maintains Hold on Durect, Raises Price Target to $2.1
|
Durect shares are trading higher after the company announced the completion of its Phase 2a Trial of DUR-928 for patients with alcoholic hepatitis.
|
Stocks That Hit 52-Week Highs On Monday
|
Durect shares are trading higher after Cantor Fitzgerald initiated coverage on the stock with an Overweight rating and a price target of $5 per share.
|
The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books
|
The Daily Biotech Pulse: Nuvectra Explores Strategic Options, J&J To Contend Opioid Ruling, Sesen Bio Gets New CFO
|
Stocks That Hit 52-Week Highs On Monday
|
Durect shares are trading higher on seemingly no company-specific news.
|
Top 10 Most Overbought Stocks Via Benzinga Pro's Screener Tool For Fri., August 7, 2019
|
42 Healthcare Stocks Moving In Wednesday's After-Market Session
|
Top 10 Most Overbought Stocks Via Benzinga Pro's Screener Tool For Fri., August 2, 2019
|
Durect shares are trading lower after the company reported worse-than-expected Q2 sales results.
|
Top 10 Most Overbought Stocks Via Benzinga Pro's Screener Tool For Wed., July 30, 2019
|
28 Healthcare Stocks Moving In Today's Pre-Market Session
|
DURECT's Deal With Gilead: An Unexpected Bonus For Shareholders
|
Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Tuesday, July 23, 2019
|
Durect shares are trading higher after the company and Gilead entered into a license agreement for long-acting Injectable HIV Investigational products. The company will receive $25 million with the potential of obtaining up to $75 million.
|
